Lataa...
The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis
BACKGROUND: Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I). Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infliximab may pr...
Tallennettuna:
| Julkaisussa: | BMC Gastroenterol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6547608/ https://ncbi.nlm.nih.gov/pubmed/31159802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-019-1000-6 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|